Biomrieux Sa Stock Net Income
| BMXMF Stock | USD 112.57 0.00 0.00% |
As of the 17th of February 2026, BioMrieux shows the Risk Adjusted Performance of (0.08), coefficient of variation of (961.68), and Standard Deviation of 1.82. bioMrieux SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm bioMrieux SA variance and value at risk to decide if bioMrieux SA is priced correctly, providing market reflects its regular price of 112.57 per share. Given that BioMrieux has information ratio of (0.14), we suggest you to validate bioMrieux SA's prevailing market performance to make sure the company can sustain itself at a future point.
BioMrieux's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioMrieux's valuation are provided below:bioMrieux SA does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioMrieux |
BioMrieux 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioMrieux's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioMrieux.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in BioMrieux on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding bioMrieux SA or generate 0.0% return on investment in BioMrieux over 90 days. BioMrieux is related to or competes with Mainz Biomed, Neuronetics, Prenetics Global, Fonar, IQVIA Holdings, Mettler Toledo, and Twist Bioscience. bioMrieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Ameri... More
BioMrieux Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioMrieux's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess bioMrieux SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 12.27 | |||
| Value At Risk | (2.99) | |||
| Potential Upside | 1.58 |
BioMrieux Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMrieux's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioMrieux's standard deviation. In reality, there are many statistical measures that can use BioMrieux historical prices to predict the future BioMrieux's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.80) |
BioMrieux February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 0.8176 | |||
| Coefficient Of Variation | (961.68) | |||
| Standard Deviation | 1.82 | |||
| Variance | 3.31 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 12.27 | |||
| Value At Risk | (2.99) | |||
| Potential Upside | 1.58 | |||
| Skewness | (2.48) | |||
| Kurtosis | 10.93 |
bioMrieux SA Backtested Returns
bioMrieux SA secures Sharpe Ratio (or Efficiency) of -0.0696, which signifies that the company had a -0.0696 % return per unit of risk over the last 3 months. bioMrieux SA exposes eighteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioMrieux's Coefficient Of Variation of (961.68), standard deviation of 1.82, and Risk Adjusted Performance of (0.08) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioMrieux's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioMrieux is expected to be smaller as well. At this point, bioMrieux SA has a negative expected return of -0.13%. Please make sure to confirm BioMrieux's variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if bioMrieux SA performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.81 |
Excellent reverse predictability
bioMrieux SA has excellent reverse predictability. Overlapping area represents the amount of predictability between BioMrieux time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of bioMrieux SA price movement. The serial correlation of -0.81 indicates that around 81.0% of current BioMrieux price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.81 | |
| Spearman Rank Test | -0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 52.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, bioMrieux SA reported net income of 601.1 M. This is 76.13% higher than that of the Healthcare sector and 247.23% higher than that of the Diagnostics & Research industry. The net income for all United States stocks is 5.28% lower than that of the firm.
BioMrieux Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioMrieux's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioMrieux could also be used in its relative valuation, which is a method of valuing BioMrieux by comparing valuation metrics of similar companies.BioMrieux is currently under evaluation in net income category among its peers.
BioMrieux Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.99 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.40 % | |||
| Price To Earning | 23.91 X | |||
| Price To Book | 3.18 X | |||
| Price To Sales | 3.63 X | |||
| Revenue | 3.38 B | |||
| Gross Profit | 1.96 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 601.1 M | |||
| Cash And Equivalents | 524.2 M | |||
| Cash Per Share | 4.43 X | |||
| Total Debt | 362.8 M | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 2.02 X | |||
| Book Value Per Share | 29.31 X | |||
| Cash Flow From Operations | 811.1 M | |||
| Earnings Per Share | 4.99 X | |||
| Price To Earnings To Growth | 2.84 X | |||
| Number Of Employees | 12.08 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 12.05 B | |||
| Total Asset | 4.62 B | |||
| Retained Earnings | 86 M | |||
| Working Capital | 412 M | |||
| Current Asset | 1.06 B | |||
| Current Liabilities | 644 M | |||
| Z Score | 19.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 4.62 B | |||
| Last Dividend Paid | 0.85 |
About BioMrieux Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioMrieux SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioMrieux using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioMrieux SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in BioMrieux Pink Sheet
BioMrieux financial ratios help investors to determine whether BioMrieux Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMrieux with respect to the benefits of owning BioMrieux security.